Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Is Emergent BioSolutions Stock a Buy?

By Zhiyuan Sun - Jan 5, 2021 at 7:03AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

This biotech is about to tackle an enormous market opportunity as coronavirus vaccines receive regulatory clearance.

If you had invested $10,000 in shares of Emergent BioSolutions ( EBS 0.24% ) at the beginning of last year, that investment would be worth $16,608 as of Dec. 31. That's an impressive outperformance compared to the S&P 500's 18.4% return last year. And the stock is likely to surge to a new all-time high in 2021 for one key reason. 

Emergent BioSolutions has managed to secure manufacturing deals with several prominent coronavirus vaccine drugmakers on top of marketing several critical public health products. These agreements could potentially add over $1 billion in future revenue for a company that has a market cap of only $4.75 billion. Let's look at why the company is a top coronavirus stock to buy right now.

Stock photo of coronavirus vaccine vials.

Image source: Getty Images.

A solid pipeline

Emergent BioSolutions is a diversified biotech company that develops vaccines, therapeutics, antibodies, and medical devices, as well as offering contract manufacturing services. Its products treat a variety of conditions, ranging from anthrax to smallpox to botulism to pain management. During the third quarter of 2020, its revenue increased to $385 million from $312 million a year ago. At the same time, the company's net income doubled to $119 million. 

Perhaps the most significant boost to Emergent BioSolutions' bottom line this year has been the COVID-19 pandemic. The company is currently responsible for manufacturing experimental coronavirus vaccines developed by AstraZenecaJohnson & Johnson, VaxartNovavax, and others. In addition, Emergent BioSolutions is also testing the effects of two experimental COVID-19 therapies for patients who develop severe disease symptoms. These candidates are in phase 2/3 clinical testing, with clinical data anticipated this year. 

Last year, the company secured over $1.5 billion in coronavirus vaccine manufacturing deals. Consequently, its free cash flow for the first nine months of 2020 increased to $186 million from $15 million during the same period last year. 

Looking forward, coronavirus vaccines will become a huge pillar of growth for Emergent BioSolutions as developers ramp up production capacity. Contingent on regulatory clearance, AstraZeneca, Johnson & Johnson, and Novavax plan to produce a combined total of 5.3 billion doses of their vaccine candidates in 2021. 

What's more, Emergent BioSolutions' non-COVID-19 related products generate safe and consistent revenue. This is because they are of public health or military significance, and have received the backing of the U.S. government. Government contracts account for 61% of the company's sales for much of 2020. 

Since 2016, government agencies have stockpiled up to $6.4 billion worth of Emergent BioSolutions' products, including $721 million in 2020. Each contract lasts between five to 10 years, with the option to purchase additional supply. 

Takeaways for investors

Emergent BioSolutions is definitely a biotech with a lot of potential. However, the best part is yet to come. 

The company expects to bring in nearly $1.58 billion in revenue and $405 million in earnings in 2020, which are significant increases from the $1.1 billion in sales and $152.3 million in net income it generated in 2019. By 2024, the company expects to generate at least $2 billion in revenue. 

That kind of growth is even better in the context of its valuation. Right now, the company is trading for 3.7 times sales and 30 times earnings. These metrics are a lot cheaper compared to most of the coronavirus vaccine developers out there. If you're looking to buy high-flying coronavirus stocks at reasonable prices, Emergent BioSolutions is a fantastic choice. 

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Emergent BioSolutions Inc. Stock Quote
Emergent BioSolutions Inc.
EBS
$41.99 (0.24%) $0.10
AstraZeneca PLC Stock Quote
AstraZeneca PLC
AZN
$55.41 (2.18%) $1.18
Johnson & Johnson Stock Quote
Johnson & Johnson
JNJ
$162.94 (2.23%) $3.56
Novavax, Inc. Stock Quote
Novavax, Inc.
NVAX
$141.86 (-11.60%) $-18.62
Vaxart, Inc. Stock Quote
Vaxart, Inc.
VXRT
$5.77 (-8.70%) $0.55

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
624%
 
S&P 500 Returns
140%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/07/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.